Colchicine, a microtubule assembly inhibitor used in inflammatory conditions like gout, received formal FDA recognition for specific formulations in the 2000s after long-standing use as an unstandardized remedy. Its regulatory path included efforts to modernize dosing, labeling, and safety standards, particularly for brands such as Colcrys and Mitigare, which helped transition it from an ancient remedy to a rigorously regulated modern therapy.
BRAND NAMES
- Colcrys (tablet formulation; widely used in the U.S.)
- Mitigare (capsule formulation for gout prophylaxis and treatment)
- Gloperba (oral solution formulation, used especially for gout prevention)
MECHANISM OF ACTION
Colchicine binds to tubulin and inhibits microtubule polymerization, disrupting the cytoskeleton of cells, especially neutrophils. This prevents neutrophil chemotaxis, adhesion, and phagocytosis of urate crystals, and reduces the release of inflammatory mediators such as IL-1β. As a result, it decreases the inflammatory response in conditions like acute gout.
PHARMACOKINETICS
Absorption
Colchicine is rapidly absorbed from the gastrointestinal tract after oral administration, with peak plasma levels usually reached within 0.5 to 2 hours. However, its absorption is variable due to first-pass metabolism and P-glycoprotein efflux, and food may slightly delay but does not significantly reduce its overall bioavailability.
Distribution
Colchicine has a large volume of distribution (~5–8 L/kg), indicating extensive tissue binding and wide distribution throughout the body. It accumulates in leukocytes and organs like the liver, kidneys, and spleen, and also crosses the placenta and enters breast milk, with moderate plasma protein binding of about 30%.
Metabolism
Colchicine is extensively metabolized in the liver, mainly by the cytochrome P450 enzyme CYP3A4, and it is also a substrate for P-glycoprotein (P-gp), which influences its elimination and drug interactions. It undergoes partial deacetylation to inactive metabolites and is subject to enterohepatic recirculation, which contributes to its prolonged action in the body.
Elimination
Colchicine is mainly eliminated through hepatic metabolism and biliary excretion, with a small amount excreted unchanged in urine. It has a long elimination half-life of about 20–40 hours due to extensive tissue binding and enterohepatic recycling, and impaired liver or kidney function can increase the risk of toxicity.
PHARMACODYNAMICS
Colchicine’s pharmacodynamics involve inhibition of microtubule polymerization by binding to tubulin, which disrupts cytoskeletal functions in cells, especially neutrophils. This reduces neutrophil migration, adhesion, and activation at sites of inflammation, thereby decreasing the inflammatory response. It also suppresses inflammasome activation and reduces release of inflammatory cytokines like IL-1β, contributing to its effectiveness in treating acute gout and other inflammatory conditions.
ADMINISTRATION
Colchicine is usually administered orally in tablet, capsule, or liquid form, depending on the indication. It is given in carefully controlled low doses for gout treatment and prevention, while intravenous use is avoided due to toxicity risks. Dose adjustments are required in patients with liver or kidney disease and those taking interacting drugs.
DOSAGE AND STRENGTH
Colchicine is available in low-dose formulations, most commonly as 0.5 mg and 0.6 mgtablets or capsules, depending on the country. For acute gout flares, a typical regimen involves an initial higher dose followed by smaller doses, while for prophylaxis it is usually given as 0.5–0.6 mg once or twice daily. In familial Mediterranean fever, doses may be gradually increased based on response and tolerance.
DRUG INTERACTIONS
Colchicine has important drug interactions with CYP3A4 and P-glycoprotein inhibitors such as clarithromycin and ketoconazole, which can increase its levels and risk of toxicity. It may also increase the risk of muscle toxicity when used with statins or fibrates, so dose adjustment or avoidance is often necessary.
FOOD INTERACTIONS
Colchicine has minimal food interactions and can be taken with or without food. However, grapefruit juice should be avoided because it inhibits CYP3A4 and P-glycoprotein, which can increase colchicine levels and risk of toxicity.
CONTRAINDICATIONS
Colchicine is contraindicated in patients with severe liver or kidney disease, especially when used with strong CYP3A4 or P-glycoprotein inhibitors due to risk of toxicity. It should also not be used in patients with known hypersensitivity to the drug.
SIDE EFFECTS
Nausea
Vomiting
Abdominal pain
Diarrhea
Bone marrow suppression (anemia, leukopenia, thrombocytopenia)
Myopathy (muscle weakness)
Neuropathy
Multi-organ toxicity (in severe overdose)
OVER DOSE
Severe gastrointestinal symptoms (profuse vomiting, diarrhea, abdominal pain)
Fluid and electrolyte imbalance
TOXICITY
Colchicine toxicity occurs due to excessive inhibition of microtubule formation, which affects rapidly dividing cells in the gastrointestinal tract and bone marrow. It can lead to severe gastrointestinal distress, bone marrow suppression, and in serious cases, multi-organ failure and death.
